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Abstract 
Musculoskeletal disorders (MSDs) affect muscles, joints, tendons and other supporting 
tissue. They are associated with pain and reduction in the normal range of activity. 
MSDs are amongst the most common causes of ill health and sickness absence, giving 
rise to substantial costs for the society. The key aim of this study is to calculate the 
economic costs of musculoskeletal disorders in Sweden relating to year 2012 by 
performing a cost-of-illness analysis with a societal perspective and a prevalence-based 
approach. The results showed that total cost for musculoskeletal disorders amounted 
to SEK 102.3 billion of which health care accounted for SEK 37 billion (36 percent). 
Of total health care costs in Sweden in 2012, musculoskeletal disorders accounted for 
11 percent. Indirect costs on the other hand accounted for almost two thirds of total 
costs for MSDs, contributing to a substantial overall burden to societal costs.  
Keywords: Musculoskeletal disorders, Cost-of-illness, Direct costs, Indirect costs, 
Human capital.  
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1 Introduction  
Today, Sweden among other industrialized countries are facing great challenges from 
demographic, environmental and lifestyle factors. One example is the dramatic 
increase in average life expectancy. Increased numbers and proportion of people at 
very old ages will have a significant impact on many sectors in the society, particularly 
the health care sector. Reason is the diseases generally associated with increased age, 
e.g. chronic diseases (Lidgren et al., 2014; Vårdanalys, 2014). 
The chronic diseases that have been assessed to cause the greatest financial burden on 
societies and individuals are musculoskeletal disorders (MSDs). MSDs are disorders 
affecting bones, joints and muscles. The disorders including those resulting from 
trauma directly affect the mobility, autonomy and quality of life of more than 100 
million people in Europe. In addition, the prevalence of MSDs is expected to grow 
further along with the ageing population, meaning that the financial burden from these 
diseases will continue to increase in coming decades (Lidgren et al., 2014; Vårdanalys, 
2014).  
Increased financial burden from chronic diseases have already been observed in many 
countries. Health care costs for chronic diseases have been assessed to account for a 
majority of total health care costs, both in Sweden and internationally. In Europe and 
the United States, health care costs of chronic diseases are estimated at 80 percent of 
total costs. According to a study from the National Board of Health and Welfare 
(NBHW) in Sweden, Swedish health care costs are expected to increase by 30 percent 
during the period 2010-2050 (Vårdanalys, 2014).  
From an economic perspective, the increased proportion of elderly and the decreased 
proportion of people of working age implies a reduced tax base and hence reduced 
revenues to health care (Lyttkens, 2010). In order to finance forthcoming expenditures, 
utilizing existing resources optimally as well as creating conditions for a sustainable, 
efficient and equitable health care in the future is crucial (Vårdanalys, 2014).  
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In light of this, the key aim of this study is to calculate the economic costs of 
musculoskeletal disorders in Sweden relating to year 2012 by performing a cost-of-
illness (COI) analysis with a societal perspective and a prevalence-based approach. 
Cost-of-illness studies are one of the cornerstones of the discipline of health 
economics and are of great interest to health economists despite the criticism (see 
section 3). The reason is that a cost-of-illness study enables a full economic evaluation, 
including both direct costs and indirect costs, of a disease. It further enables a 
comparison perspective of the economic burden between different diseases, e.g. 
between MSDs and cardiovascular disease. This is not applicable if there are no widely 
accepted and standardized methods to calculate costs (Ament and Evers, 1993).  
An additional underlying aim of this study is to compare the result with previous 
Swedish cost-of-illness studies on musculoskeletal disorders to evaluate cost 
developments over time. As mentioned before, the financial burden from MSDs is 
expected to grow along with the ageing population, meaning that the cost estimates in 
this study should be higher than in previous studies. A comparison perspective is 
therefore of great interest for health economist as well as for policy makers in order to 
plan for future health care.   
This study will include MSDs defined by ICD-10 Chapter XIII Diseases of the 
musculoskeletal system and connective tissue (M00-M99). Cost estimates for resource 
use and production loss will include statistics where any diagnosis M00-M99 is 
specified as the primary diagnosis. Resource use is further identified as hospital 
admissions that are encoded by diagnosis-related groups by NordDRG category MDC 
08. Lastly, costs for pharmaceuticals will include all drugs for the Musculoskeletal 
system (ATC code M) and selected drugs under ATC code L (Antineoplastic and 
immunomodulating agents).  
A number of limitations will be made in this study. First, direct costs related to 
pharmaceuticals will only include biologic drugs under ATC code L1. The selection is 
based on the available published data from the NBHW. Second, indirect costs for 
informal care and community care will not be estimated due to the lack of data on the 
extent of resource use in both sectors, particularly in community care. There are 
                                                 
1 The biologic drugs that are included are Enbrel (L04AB01), Humira (L04AB04), Mabthera (L01XC02), 
Orencia (L04AA24), Remicade (L04AB02) and Roactemra (L04AC07). 
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therefore no basis to calculate the share of community care directly relating to 
musculoskeletal disorders. Third and last, the cost of lost quality-adjusted life years 
(QALYs) is not possible to include in the context of this study.  
Due to the aforementioned limitations, the cost estimates in this cost-of-illness study 
will be underestimated. The total cost for musculoskeletal disorders will in other words 
not reflect reality accurately. Hence, it will be difficult to draw any specific conclusions, 
but the result is mainly intended to be used as guidelines to assess the size of the 
problem.  
The remainder of this study will be structured as follows; section 2 contains the 
background introduction to the musculoskeletal disorders, the prevalence and the 
economic burden. Section 3 describes the methodological framework, motivates the 
choice of method and explains how it is applied. In section 4, the data sets used in this 
study is presented and depicts what alterations have been made. In section 5, the results 
of this study is presented, which are then discussed in section 6. Finally, section 7 
presents the conclusions drawn.   
    
    7 
 
2 Background 
Diseases of the musculoskeletal system is a collective name for several different 
diseases affecting bones, joints and muscles. It also includes bone fractures and joint 
injuries caused by accidents. MSDs are an increasing health care issue globally, being 
the second leading cause of disability after mental and behavioral disorders 
(Socialstyrelsen, 2012a; Vos et al., 2012).  
The most common diseases in the musculoskeletal system is non-specific pain, 
rheumatoid arthritis (RA), osteoarthritis (OA) and osteoporosis. The global prevalence 
of RA have been estimated at about 0.5-1.0 percent worldwide with a higher prevalence 
observed in northern Europe countries and the United States compared with southern 
Europe and developing countries (Lundkvist et al., 2008). In addition, 40 million 
people in the European Union (EU) are estimated to have osteoarthritis, 
corresponding to 0.5 percent of total gross domestic product (GDP), and in 2010, also 
22 million women and 5.5 million men were estimated to have osteoporosis (Conaghan 
et al., 2014; Svedbom et al., 2013). These figures are just a sample of diseases within 
the musculoskeletal system but nevertheless demonstrates the size of the problem.   
Musculoskeletal disorders also includes injuries caused by accidents. The World Health 
Organization (WHO) estimated that approximately 5.8 million people die worldwide 
each year from injury, accounting for 11 percent of global mortality. This implies that 
injuries have a significantly impact on the society on a physical, psychological and 
economical level. The total costs have been estimated at US$518 billion globally, 
meaning that injuries are a major cause of total health care costs in the world 
(Willenberg et al., 2012).  
In a study from 2005, a uniform method calculating medical costs of injury was 
developed and applied in 10 European countries. This method allowed for calculations 
of medical costs of injury by age, sex, external cause and type of injury at country level 
and EU level. The result showed quite similar patterns of costs by age, sex, injury type, 
and external cause between the countries. For all countries, costs per capita increased 
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exponentially in ages 65 years and older, due to the combined effect of high incidence 
and high costs per patient. The elderly females accounted for almost tripled costs 
compared with same age males, but also young children and male adolescents were 
categorized as high-cost groups. Home and leisure injuries (including sport injuries) 
combined with occupational injuries accounted for 86 percent of total hospital costs 
of injury (Polinder et al., 2005).  
In Sweden, musculoskeletal disorders are the most common causes of pain and 
consequently also the leading causes of impairment of work abilities, long term 
sicknesses, and sickness and activity compensations. The consequences are substantial 
costs for both the people affected and the society as a whole (Socialstyrelsen, 2012a). 
In 2003, Linköping University estimated that the total economic costs of rheumatic 
diseases and osteoporosis for year 2001 amounted to SEK 36 billion. The largest 
expense was indirect costs (productivity costs) which accounted for 86 percent of total 
costs while direct costs (health care and pharmaceuticals) represented the remaining 
14 percent. The study also showed that two-thirds of both direct costs and indirect 
costs was attributable to women, indicating that women are overrepresented when it 
comes to MSDs (Schmidt et al., 2003). 
The impact of musculoskeletal disorders is in other words extensive, not only in terms 
of costs. From the individual perspective, it is rather the impact on the quality of life 
that is central. MSDs are in general characterized with poor quality of life, such as pain 
and loss of mobility, but also an increased risk of premature death in cardiovascular 
disease (Socialstyrelsen, 2012a; Ajeganova et al., 2013).  
The incidence of MSDs is highest among older people. More than half of all chronic 
conditions in people over age 65 are connected to bones, joints and muscles 
(Socialstyrelsen, 2012a). There is, however, a tendency for non-specific symptoms such 
as chronic widespread pain to decrease at the retirement age of 65. A possible 
explanation could be that the body is no longer exposed to adverse physical and 
psychological factors at work (Bergman, 2007).  
Besides age-related incidence, people with lower socioeconomic status tend also to be 
overrepresented among MSDs. People suffering from chronic pain might have a lower 
socioeconomic status because of the problems caused by pain, or that low 
socioeconomic status increases the risk of developing chronic pain (Jöud, 2013).  
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3 Method   
3.1 Cost-of-illness studies 
Cost-of-illness studies are descriptive studies that value in economic terms the costs of 
a particular health problem, which enables the economic burden of the problem to be 
estimated. It hence provides a holistic view of the overall burden of a particular disease 
on society, given current treatment alternatives. Cost-of-illness studies also identify 
how costs are allocated between for example the health care sector, the individual, the 
family and others, and their relative sizes. This information can highlight areas where 
costs can be saved or inefficiencies reduced and is practical information to guide 
funding decisions and policy-making (Ament and Evers, 1993). 
An additional advantage with cost-of-illness studies is that it can act as a building block 
in a subsequent economic evaluation. This means that in an evaluation, the change in 
direct costs and indirect costs of an intervention or a program would be weighted 
against the change in health effects (Ekman et al., 2005). 
As mentioned in the beginning, cost-of-illness studies are one of the cornerstones of 
the discipline of health economics. However, they have raised much criticism on both 
methodological grounds and for being doubtful value for policy-making purposes. The 
reason is that cost-of-illness studies are not considered full economic evaluations 
because they do not assess actions to address the problem. Another criticism is that 
they are ineffective use of resources because they do not provide enough information 
to identify inefficiency or waste since no comparisons between different treatments 
are being applied. From a policy-making perspective, economic evaluations would be 
more valuable since it asses both costs and health effects of single medical 
interventions or healthcare programs (Ament and Evers, 1993; Ekman et al., 2005).   
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3.2 Types of costs 
In cost-of-illness studies a distinction is made between direct, indirect and intangible 
costs. Intangible costs are the value of improved health per se, or the pain and suffering 
associated with treatment. As these consequences are difficult to measure and value, 
cost-of-illness studies are usually defined to quantify the costs that are monetarily 
measurable. Therefore, only direct costs and indirect costs will be estimated in this 
study (Drummond et al., 2005). 
There are however reasons to believe that intangible costs are of great importance 
when it comes to musculoskeletal disorders. MSDs are chronic diseases, meaning that 
patients are suffering from pain for long periods, usually during the remaining time of 
life. Consequently, intangible costs would be high. At the same time, successful 
biologic drugs for rheumatoid arthritis have been documented to increase patients’ 
quality of life (Kobelt et al., 2004). This would on the other hand lead to lower 
intangible costs. 
Direct costs are defined as the actual money expenditures related to an illness or 
disorder. These costs include resource use in the health care sector and other sectors 
such as community care. They also include consumption of pharmaceuticals and 
patient’s out-of-pocket expenses (Drummond et al., 2005).   
In contrast, indirect costs include costs related to lost output caused by illness, 
disability or injury (Drummond et al., 2005). In this cost-of-illness study, productivity 
costs due to both sickness and premature death will be included. Since MSDs are 
characterized with pain and loss of mobility, indirect costs are expected to be a major 
expenditure sector. 
3.3 Human capital approach 
A generally accepted method to calculate productivity costs in health economics is the 
human capital (HC) approach. The HC approach is based on the assumption that 
earnings reflect productivity. Productivity costs are therefore quantified in terms of 
forgone earnings. In practice, however, neither salary nor working hours at the 
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individual level can be observed. Instead, an average level of wages and other costs, 
such as pension fees, are included in order to value the loss of production (Drummond 
et al., 2005).   
There are many reasons to questioning the human capital approach. First of all, the 
human capital approach values a life with respect to the individual’s lost earnings 
potential. This approach ignores that people are worth more than just what they 
produce. Secondly, the approach is based on the assumption that earnings reflect 
productivity. Since men on average get paid more than women, this approach assumes 
that men are more productive than women. Lastly, based on the assumptions in this 
approach, indirect costs are zero when retirees die. Consequently, from a societal 
perspective, it is more favorable when older people die compared to younger as it 
would result in lower costs.     
3.4 Prevalence versus incidence 
In cost-of-illness studies, two approaches can be used to estimate costs, prevalence-
based and incidence-based. The underlying rationale of the prevalence-based approach 
is that it estimates the economic burden of a condition over a specified period, usually 
a year. For example, direct costs and indirect costs resulting from musculoskeletal 
disorders are assigned to the year in which they occur (Ament and Evers, 1993). 
The incidence-based approach on the other hand estimates the lifetime costs of a 
condition from its onset until its disappearance, usually by cure or death. This means 
that all costs are discounted to their present value and assigned to the year in which 
the disease first appears. In order to apply an incidence-based approach, it assumes 
data at the individual level where well-defined disease progression can be followed over 
time and where the onset of illness is known, as for example stroke (Ament and Evers, 
1993). 
Musculoskeletal disorders are often characterized by slow onset of symptoms with 
joint swelling, joint or muscle tenderness, movement pain followed by rest pain, 
functional impairment, reduced muscle strength and fatigue, which may last for a 
longer period before diagnosis is determined. In other words, the onset of the 
disorders is ambiguous, meaning that it is difficult to assign which year the disease first 
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appeared. This is the main reason why a prevalence-based approach is more practicable 
in this cost-of-illness study.  
Direct costs and indirect costs due to sickness will be estimated by using a prevalence 
based approach. In addition, the prevalence-based data will be using a top-down 
approach meaning that e.g. productivity costs will be calculated using average level of 
income instead of individual salaries2. The advantages of using a top-down approach 
are that no extrapolation is needed, and that it avoids the risk of double-counting. The 
disadvantages on the other hand are that diagnoses may be underreported or 
misreported, and that important cost items are missing from national illness registers. 
For example, costs for social services or unpaid home help are not included if a pure 
top-down approach is being used3 (Ekman et al., 2005).  
 
Indirect costs due to premature death will however be estimated using an incidence-
based approach. Costs will be calculated from the year death occurs and then 
discounted by three percent until reached retirement age.  
3.5 Perspectives of cost-of-illness studies 
Cost-of-illness studies can be conducted from different perspectives. Impacts and 
costs can be assessed from the perspective of the health system, the individual, or the 
society. A societal perspective is including both direct costs and indirect costs meaning 
that costs will be included no matter if it is the health system or the individual who 
incurs them. In general, a broader societal perspective is preferred since the impact of 
a condition is not solely on the individuals or organizations directly involved. An 
advantage with a societal perspective is that it can detect costs shifting between sectors 
and account for alternative resource use outside the health sector (Byford and Raftery, 
1998).   
                                                 
2 In the bottom-up approach, data are collected directly from a sample of patients during or after medical 
visits, and then the figures from the sample are extrapolated to represent the whole population by using 
national prevalence figures. This approach can be used either as an alternative or as a complement to 
the top-down approach. 
3 Despite that a top-down approach is being used, costs for social services and unpaid home help will 
not be included due to lack of data, as mentioned in the introduction.  
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4 Data 
4.1 Prevalence 
According to a survey on living conditions (ULF) from Statistics Sweden (SCB), 
957 000 persons aged 16 and older were living with musculoskeletal disorders in 2012. 
The survey also showed that the prevalence was higher among women than men of 
which women accounted for over two-thirds (67 percent). The majority of those living 
with MSDs (76 percent for men and 80 percent for women) was over 45 years (SCB 
2012a). High prevalence among women and elderly is in line with previous studies (see 
e.g. Socialstyrelsen, 2012a).   
The survey from SCB also estimated that 1.5 million people aged 16 and older had 
severe pain in their body (SCB, 2012a). This is consistent with the result in a 
dissertation from Lund University on back and neck pain, where 10-14 percent of the 
population suffered from low back pain at any given time (point prevalence) (Jöud, 
2013). 
4.2 Resource use in health care 
Following sections will give a detailed description of the data that have been used to 
estimate the costs for outpatient care, inpatient care and pharmaceuticals. In general, 
data for musculoskeletal disorders are presented in national administrative records 
such as the NBHWs patient, death, operation, and pharmaceutical records. There are, 
however, no current national data on resource use in outpatient care.  
Outpatient care In the absence of nationally collective data from outpatient care, 
costs for resource utilization have been estimated based on statistics from Region 
Skåne together with published data from the Swedish Association of Local Authorities 
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and Regions (SKL). The number of physician contacts (both physical and other forms 
of communication as for example over the phone) in Region Skåne in 2012 amounted 
to more than 3 million in primary care and 2.5 million in specialist care (Region Skåne, 
2012). On national level, this would correspond to 23.2 million physician contacts in 
primary care and 19.4 million physician contacts in specialist care.  
Data on the number of physician contacts was complemented by data on the number 
of visits to other health care providers than physicians, particularly nurses, 
physiotherapists and occupational therapists. According to SKL, the number of visits 
to other health care providers amounted to 25.9 million in primary care and 7.3 million 
in specialist care (SKL, 2013). In addition, the NBHW estimated that 20-30 percent of 
the visits in primary care are caused by people with musculoskeletal disorders 
(Socialstyrelsen, 2012a). Based on these numbers, the total number of contacts caused 
by MSDs was estimated to 17.1 million.  
Inpatient care Estimates on direct costs for musculoskeletal disorders in inpatient 
care was based on published statistics from the NBHW and the Cost-Per-Patient 
(KPP) database from SKL (Socialstyrelsen, 2012b; SKL 2012). The KPP-database is 
divided into DRGs, grouped into Major Diagnostic Categories (MDCs). This study is 
based on MDC 08, Musculoskeletal System and Connective Tissue (Socialstyrelsen, 
2014a). DRGs under MDC 08 is presented in Table 2 in Appendix. 
The KPP-database includes the number of admissions, hospital-bed days and inpatient 
costs. To calculate the costs for inpatient care, data from the NBHW was combined 
with cost estimates from the KPP-database. The latest available data was from the data 
collection in 2012. The results are presented in Table 3 – Table 4 in Appendix. 
Pharmaceuticals Costs for pharmaceuticals for treatment of the musculoskeletal 
system is based on published data from the NBHW’s report on pharmaceutical costs 
for 2012. The report presents defined daily doses (DDD) and costs (AUP) for 
prescription drugs, drugs in inpatient care and over-the-counter (OTC) drugs. The 
report further presents DDD for all major groups, which in this case is ATC code M. 
As only some drugs under ATC code L can be attributed to musculoskeletal disorders, 
an inclusion of the entire group would lead to an overestimation of the costs. 
Therefore, only selected drugs under L was included (Socialstyrelsen, 2013). 
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4.3 Productivity costs 
Under indirect costs, available information on productivity costs due to reduced work 
capacity and premature death is compiled. As mentioned before, productivity costs 
have been calculated according to the human capital approach.  
Reduced work capacity In Sweden, MSDs are the leading cause to sick leave and 
sickness and activity compensation (SA). There are primarily two different forms of 
compensation available for employed individuals who become sick or injured. The first 
one is sickness benefit which is given to people who are unable to work due to illness. 
The other one is SA which is given to people who probably never will be able to work 
full time due to illness, injury or disability4 (Lidwall, 2011).   
Studies on sick leave from Sweden are often based on data from the Swedish Social 
Insurance Agency (SSIA). One problem with this data is that sick leave shorter than 
14 days is not registered. The reason is that the employer is financially responsible for 
the first 14 days in a period of absence due to illness. Information on leaves of absence 
shorter than 14 days is therefore not available from the SSIA (Lidwall, 2011). The 
implication of the legal structure of the labor market in Sweden is consequently that 
indirect costs might tend to be underestimated. Another implication is that diseases 
with shorter course of disease, e.g. fever and cold will have small or zero indirect costs 
as they are not registered by the SSIA. This is an important aspect when both 
performing a cost-of-illness study and comparing different diseases. In addition, 
diseases such as fever and cold might rather result in sickness at work, meaning less 
productivity and hence hidden productivity costs.  
In order not to underestimate the indirect costs for musculoskeletal disorders, each 
period of absence that is registered by the SSIA have been added 14 days. This does 
however mean that periods of absence shorter than 14 days (i.e. periods not registered 
by the SSIA) have not been possible to include in the cost estimates. There are 
therefore reasons to believe that the indirect costs in this study are underestimated, but 
as MSDs are generally associated with longer sick periods, this might not be a problem.  
                                                 
4 Sickness and activity compensation was previously called disability pension. An important difference 
is that SA is always time limited, unlike disability pension.  
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Premature death The premise is that premature death have costs to society in terms 
of productivity costs up to the retirement age of 65. In order to calculate premature 
death caused by MSDs, this study have been based on mortality data and a lifetime 
table for 2012. The value of lost working years where calculated using data from the 
Labor Force Survey (AKU) from SCB which indicated average employment rate by 
gender and age group (Socialstyrelsen, 2012c; SCB, 2012b). 
To calculate productivity cost, the number of deaths in each age group was multiplied 
with expected working activity in each age group, the employment rate and the average 
monthly salary. Future productivity costs was then discounted by 3 percent. There was 
however no assumptions about productivity growth over time.  
4.4 Unit costs 
The economic costs of musculoskeletal disorders have been estimated for the year of 
2012 which was the last full calendar year with available data. Because of that, 2012 
prices have been used in various types of resource use. All unit prices are presented in 
Table 1. 
Costs for outpatient care was based on the price list of Region Skåne5. The cost for a 
physician contact in primary was SEK 1359 while a visit with another health care 
provider was SEK 554. In specialist care, the cost for a physical doctor visit, other 
physician contact, and a visit to other health care providers was SEK 2316, SEK 295, 
and SEK 1039, respectively (Södra regionvårdsnämnden, 2011).  
Indirect costs related to productivity losses were valued based on wage data from SCB. 
The average monthly salary for men was SEK 32,100 and SEK 27,600 for women 
(SCB, 2012b). The calculations also included social security contributions (31.42%) 
and an average cost of collective wage agreement (10.38%) for men and women in 
Sweden in 20126 (Ekonomifakta, 2012).  
                                                 
5 After a review of price lists in different regions in Sweden, no significant difference was found.  
6 According to ekonomifakta.se indicated, average cost of social security contributions in 2012 were 
37.4% for blue-collar workers and 46.2% for white-collar workers. Therefore, an average of 37.4% and 
46.2% was used, namely 41.8%. 
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5 Results 
Total costs and allocations of costs for musculoskeletal disorders are presented in 
Table 1. Total costs amounted to SEK 102.3 billion in 2012. Translated into cost per 
person based on the population in Sweden in 2012 corresponds to about SEK 11 000. 
Of total costs, health care accounted for 36 percent, or the equivalent of SEK 37 billion 
while non-health care accounted for 64 percent, or the equivalent of SEK 65.4 billion. 
The allocation of costs for musculoskeletal disorders in percent is further presented in 
Figure 1. 
Figure 1: The allocation of costs for musculoskeletal disorders in percent. 
 
Non-health care costs included costs for lost productivity caused by premature death, 
sick leave, and sickness and activity compensation. Figures on productivity costs were 
calculated separately for men and women. The results and underlying calculations are 
reported in more detail in Table 5 – Table 9 in Appendix.  
The Tables shows that women had higher productivity costs than men as women’s 
share of total costs were 62 percent. This despite that men on average worked in 
occupations with higher wages (and hence should result in higher productivity costs). 
The only explanation to this result is that women is overrepresented among MSDs. 
They therefore represents a larger share of total costs, despite lower wages. This is in 
line with previous studies (see e.g. Schmidt et al., 2003).  
64%
22%
10%
4%
Production loss
Outpatient care
Inpatient care
Pharmaceuticals
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From the Tables on productivity costs, it can also be inferred that costs of lost 
production due to premature death was a small expenditure item compared to sick 
leave and sickness- and activity compensation. The most obvious explanation to this 
result is that musculoskeletal disorders are primarily characterized with pain and loss 
of mobility, leading to reduced capacity to work and large productivity costs. However, 
there are reasons to believe that the result is misleading. The number of deaths related 
to musculoskeletal disorders might be underestimated in the data. When people with 
MSDs dies from any cause of death, it will most likely not be attributed to the 
musculoskeletal system although the underlying cause was musculoskeletal related. 
The number of deaths related to MSDs are therefore probably underestimated, leading 
to hidden productivity costs. This is of course a problem, but it would also be 
problematic if the cause of death would be attributed to both musculoskeletal disorders 
and e.g. cardiovascular disease. This could lead to double-counting and consequently 
overestimate the costs when performing a cost-of-illness study on more than one 
disease.   
In the NBHWs patient record and the KPP-database, costs for inpatient care are 
divided by primary diagnosis within the group of MSDs. As can been seen in Table 3, 
three diagnostic groups accounted for about 60 percent of total resource utilization. 
Osteoarthritis, spondylopathies (disorders of the spine) and other dorsopathies 
together accounted for 60 percent of both hospital-bed days, admissions and the 
number of patients treated with a primary diagnosis in the group of MSDs. In total, 
the NBHWs patient records registered over 450 000 bed days for about 78 500 patients 
in the group of MSDs in 2012. The number of patients (78 498) represents almost 10 
percent of total number of patients for all diseases in the NBHWs record for 2012 
(Socialstyrelsen, 2012d).  
To estimate the hospital costs for musculoskeletal disorders, data from the NBHWs 
patient record was combined with information from the KPP-database. The estimated 
costs based on hospital admissions and bed days for a sample of code groups in MDC 
08 are reported in Table 4. The largest cost was replacements of joints in the hip, knee 
or foot (29 percent), followed by surgery on the hip and femur as well as back and 
neck procedures which respectively constituted for 12 percent (Socialstyrelsen, 2012b; 
SKL, 2012).  
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Resource use and costs in outpatient care are represented in Table 1. Primary care and 
specialized care accounted for over SEK 23 billion together, representing 62 percent 
of total costs for health care. As the estimates are based on data from Region Skåne 
(scaled up to national level), these figures might not represent the actual resource use 
in Sweden accurately. The reason is that in per-capita calculations, there are several 
factors that could contribute to misleading results. Morbidity, health care consumption 
and productivity costs may differ between the national average and regional levels. 
However, as Region Skåne represents about 13 percent of the total population in 
Sweden, this region can be considered representative of the national average. An 
additional argument in favor of Skåne as a representative region is that the distribution 
of costs between outpatient care and inpatient care for musculoskeletal disorders are 
in line with previous results (see e.g. Schmidt et al., 2003). 
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Table 1: Total costs and allocations of costs for musculoskeletal disorders.   
Type of resource use Number of 
units 
Average unit 
cost, SEK 
Total cost, 
SEK millions 
Health care costs    
Outpatient care    
Primary care    
Physician contact 5 793 217 1 359 7 873 
Other health care contact 6 475 000 554 3 587 
Specialist care    
Physician contact (physical) 4 052 338 2 316 9 385 
Physician contact (other)  803 938 295 237 
Other health care contact 1 815 250 1 039 1 886 
Inpatient care    
Hospital admissions 169 724  9 706 
Drugs    
Pharmaceutical benefit   2000 
Inpatient drug   1788 
Individual expenditure    
Non-prescription drugs (ATC code M) 85 300 000  511 
Total health care costs     36 973 
Non-health care costs    
Productivity costs    
Mortality    
Lost working years M: 293 M: 546 214 M: 26 
 F: 477 F: 469 642 F: 31 
 M+F: 770  M+F: 57 
Total premature death   57 
Reduced work capacity    
Sick leave (number of days) 12 650 781 M: 2 324 M: 11 469 
  F: 1 998 F: 15 421 
   M+F: 26 890 
Sickness and activity compensation  
(number of persons) 
 
100 585 M: 546 214 M: 13 110 
  F: 469 642 F: 25 311 
   M+F: 38 421 
Total work disability   65 311 
Total productivity costs   65 368 
Total non-health care costs   65 368 
Total economic burden     102 341 
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6 Discussion 
The total economic burden of musculoskeletal disorders was estimated to SEK 102.3 
billion in 2012.  The study included costs such as costs for outpatient care, inpatient 
care, pharmaceuticals and productivity costs due to morbidity and premature death. 
Costs for lost productivity accounted for the largest expenditure item as 
musculoskeletal disorders are primarily related to reduced capacity to work. 
Productivity costs due to premature death was thus a comparatively small part of the 
costs.  
6.1 Limitations 
As mentioned earlier in this study, there are reasons to believe that the numbers of 
deaths related to musculoskeletal disorders are underestimated. A previous study from 
2011 examined whether sick leave in musculoskeletal disorders increased the risk of 
sickness and activity compensation or premature death. The results showed that sick 
leave in MSDs had health consequences for both women and men in terms of a greatly 
increased risk of sickness and activity compensation, and an increased risk of 
premature death from any cause of death (Jansson and Alexanderson, 2011). This 
result implies that premature death in MSDs is more common than what data shows. 
It further implies that the productivity costs due to premature death in this cost-of-
illness study might be significantly underestimated.   
There are additional reasons to believe that total costs are significantly underestimated 
in this cost-of-illness study. As mentioned in the introduction, a number of limitations 
have been made for various reasons despite that some of them are assumed to be 
central for MSDs. First and foremost is the cost of lost QALYs. The implications of 
the disorders are reduced quality of life and disability, leading to large costs for lost 
QALYs for the individual. To illustrate this, osteoporosis was estimated to cause 
36.000 lost QALYs, at a cost of approximately SEK 24.6 billion in Sweden in 2010 
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(Svedbom et al., 2013). As this was only one disorder within musculoskeletal disorders, 
the total cost for lost QALYs are expected to be high. 
 
Secondly are the costs for informal care, and community care such as home care or 
assisted living facilities. As patients with musculoskeletal disorders are struggling with 
a reduction in the normal range of activity, additional help with e.g. household tasks 
are central for these patients. A study from the Netherlands estimated the magnitude 
of the burden of informal care of rheumatoid arthritis patients. In general, the study 
showed that informal care can be burdensome in the context of RA. The caregivers 
had on average been providing informal care for more than 11 years. Total time 
invested in caregiving was 27.4 hours per week. Most of the informal care provided 
was related to household tasks such as house cleaning and the preparation of food and 
drinks. More than 80 percent of the caregivers indicated that their time spent on 
household activities had increased compared with the period before the patient was ill 
and 6.1 percent had to quit their paid job to free time to care for the patient. A total 
of 43.5 percent of the caregivers had experienced additional costs as a result of 
caregiving while 18.9 percent reduced their leisure time (Brouwer et al., 2004). 
The study from Netherlands illustrates the importance of informal care for patients 
with musculoskeletal disorders. As shown in the study, caregivers quit their jobs in 
order to free time to care for the patient. This leads to lost income for the caregiver 
and high productivity costs for the society. Hence there are reasons to assume that 
costs for informal care would be large for both the individual and the society.   
Although above mentioned costs are central for musculoskeletal disorders, there was 
no possibility in the context of this study to include them. In addition, including the 
costs is not entirely unproblematic. For example, when it comes to community care, it 
is difficult to distinguish between care only related to MSDs and care granted on other 
grounds such as reduced ability to fend for himself because of dementia. Costs for 
community care are therefore difficult to assign to a specific disease and could have 
led to an overestimation.  
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6.2 Cost comparison 
Estimated costs for musculoskeletal disorders in this cost-of-illness study significantly 
underestimates the total costs for the society. Despite underestimation, the result 
indicates that MSDs have a major impact on the society.  
As an underlying aim of this study was to compare the result with previous Swedish 
cost-of-illness studies on MSDs, it might suggest whether my results are reasonable or 
not. The reason for the comparative perspective was primarily to evaluate cost 
developments over time, which is of great interest for policy makers in orders to plan 
for future health care. Since the financial burden from MSDs is expected to grow along 
with the ageing population, costs estimates in this study are expected to be higher 
compared to earlier studies.  
In 2008, Linköping University estimated the economic costs for different disease 
groups in Östergötland, Sweden. According to the study, total costs for 
musculoskeletal disorders amounted to SEK 4.7 billion in 2006, representing 23 
percent of total costs (SEK 20.2 billion) for all diseases (Schmidt and Andersson, 
2008). The population of Östergötland represents 4.6 percent of the population in 
Sweden. To compare the costs in Östergötland with the costs in this cost-of-illness 
study (i.e. total costs in Sweden), costs had to be scaled up to national level. In order 
to compare them with the costs from 2012, they also had to be adjusted to the price 
level in 2012. According to the consumer price index, costs amounted to over SEK 
102.2 billion for musculoskeletal disorders. In other words, the costs for 2006 are well 
in line with the result in this study (SEK 102.3 billion). 
There are yet one difference between the two cost-of-illness studies. The study by 
Schmidt and Andersson (2008) had not included productivity costs due to premature 
death. As this cost represented only a small part of total costs in this study, it does not 
contribute to any significant difference in outcome (i.e. SEK 0.1 billion).  
In contrast, as the costs for musculoskeletal disorders are expected to increase over 
time, it is very interesting that costs for 2012 are in line with costs for 2006. This result 
suggests that costs for MSDs are constant over time, or at least for this time of period. 
It could be the case that the time period is too short to evaluate whether or not the 
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costs increases over time. In addition, costs are expected to increase along with the 
ageing population, and the average life expectancy is most likely the same now as in 
2006.  
Due to the limitations in this study, there are several reasons to assume that the results 
do not reflect reality accurately. Besides the limitations, some assumptions that have 
been made in this study might have affected the results. For example, the assumption 
that resource use in outpatient care in Region Skåne is representative for Sweden could 
have contributed to misleading results. On the whole, the results in this study are not 
sufficiently reliable in order to draw conclusion regarding cost developments over time.  
6.3 Future challenges 
Between 1990 and 2010, total disability-adjusted life years (DALYs) due to 
musculoskeletal disorders increased with 4.7 percent and accounted for 6.8 percent in 
2010 (Murray et al., 2012). This illustrates that the prevalence of MSDs have not 
reached its peak yet, and will continue to increase as the average life expectancy is 
continuing to increase. It further illustrates that if this trend continues, it will give rise 
to more substantial costs for the society and burden future health care systems even 
more than today. 
In order to finance forthcoming expenditures it is therefore crucial to utilize existing 
resources optimally. It is also essential to prevent and alleviate the disease course. For 
example, biologic drugs for rheumatoid arthritis are documented to increase the 
patients’ quality of life. Even though the costs for biologic drugs are significant, 
increased use of biologic drugs could alleviate the disease course and hence lead to 
lower outpatient care as well as inpatient care. Lower direct costs could then 
compensate for the increased costs for pharmaceuticals (Kobelt et al., 2004).  
Lastly, an important aspect is unrelated medical costs in life-years gained. This 
important cost category is normally ignored in economic evaluations (Rappange et al., 
2008). The point is that if patients do not die in this disease, they will die in any other.   
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7 Conclusion 
The key aim of this study has been to calculate the economic costs for musculoskeletal 
disorders in Sweden relating to year 2012. The total costs amounted to SEK 102.3 
billion of which health care amounted to over SEK 37 billion. According to the 
NBHW, total health care spending amounted to approximately SEK 327 billion in 
2012 (Socialstyrelsen, 2014b), meaning that musculoskeletal disorders accounted for 
about 11 percent. Indirect costs on the other hand accounted for almost two thirds of 
total costs for MSDs, contributing to a substantial overall burden to social costs.  
Although estimates of the societal costs have tried to be as comprehensive as possible, 
some limitations have been necessary in the context of the study. The limitations are 
mainly related to different health care interventions. The total societal costs are 
therefore significantly underestimated, meaning that the result do not reflect the reality 
accurately.  
In addition, many studies have been emphasizing that costs related to MSDs are 
increasing steadily along with the ageing population. This development is however not 
reflected in this cost-of-illness study as the results are in line with previous studies, 
suggesting that costs are constant over time. On the other hand, as the results from 
this study are not sufficiently reliably, it is not possible to draw any conclusions 
regarding cost developments over time.  
This study rather outlined the substantial financial burden from MSDs on both 
individuals and the society, regardless underestimated costs. Given the epidemiological 
pattern, the financial burden is expected to become even more substantial in the 
coming decades. In order to meet future demand in the health care sector, it is essential 
to prioritize research into the most cost-effective strategies for prevention and 
treatment (Murray et al., 2012). To alleviate and inhibit the disease course it is also 
important with early diagnosis, early treatment and rehabilitation (Socialstyrelsen, 
2012a).  
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A DRGs in MDC 08 
Table 2: DRGs in MDC 08 (Socialstyrelsen, 2014a). 
DRG Text 
209C Bilateral joint replacement of hip and reattachment of lower extremity 
209D Major joint replacement in hip, complicated 
209E Major joint replacement of hip, not complicated 
209F Bilateral joint replacement of knee or foot 
209G Major joint replacement of knee or foot 
209O Joint replacement of lower extremity, outpatient 
210 Hip & femur procedures except major joint, > 17 year, complicated 
211 Hip & femur procedures except major joint, > 17 year, not complicated 
212 Hip & femur procedures except major joint, 0-17 year 
212O Hip & femur procedures except major joint, outpatient 
213 Amputation for musculoskeletal system & connective tissue 
213O Amputation for musculoskeletal system & connective tissue, outpatient 
214A Spinal fusion 
214B Other spinal fusion, complicated 
214C Other back & neck procedures, complicated 
215B Other spinal fusion, not complicated 
215C Other back & neck procedures, not complicated 
215O Back & neck procedures, outpatient 
216 Biopsies of musculoskeletal system & connective tissue 
216O Biopsies of musculoskeletal system & connective tissue, outpatient 
217 Wound debridement and skin graft except hand, for musculo-conn tiss dis 
217O Wound debridement and skin graft except hand, for musculo-conn tiss dis 
218 Foot, lower leg or upper arm procedures, >17 year, complicated 
219 Foot, lower leg or upper arm procedures, >17 year, not complicated 
220 Foot, lower leg or upper arm procedures, 0-17 year 
220O Foot, lower leg or upper arm procedures, outpatient 
221 Knee procedures except arthroscopy, complicated 
222 Knee procedures except arthroscopy, not complicated 
222O Other knee procedures, outpatient 
222P Major knee procedures, outpatient 
223 Major shoulder, elbow or arm procedures 
223O Major shoulder or elbow joint procedures, outpatient 
224 Other arm procedures, not complicated 
224O Other arm procedures, outpatient 
225 Foot procedures 
225O Foot procedures, outpatient 
226 Connective tissue procedures, complicated 
227 Connective tissue procedures, not complicated 
227O Connective tissue procedures, outpatient 
228 Major thumb or joint procedures/other hand or wrist procedures 
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Table 2: DRGs in MDC 08 (continuation). 
DRG Text 
228O Major thumb & joint procedures, outpatient 
229 Hand or wrist procedures, except major joint procedures, not complicated 
229O Hand or wrist procedures, except major joint procedures, outpatient 
231O Local excision & removal int fix devices except hip & femur, outpatient 
232 Arthroscopy 
232O Arthroscopy, outpatient 
233 Other musculoskeletal system & connective tissue procedures, complicated 
234 Other musculoskeletal system & connective tissue procedures, not complicated 
234O Other musculoskeletal system & connective tissue procedures, outpatient 
235 Fractures of femur 
236 Fractures of hip & pelvis 
237 Sprains, strains & dislocations of hip, pelvis & thigh 
238 Osteomyelitis 
239 Musculoskeletal malignancy & pathol fracture  
240N Connective tissue disorders & vasculitis, complicated 
241N Connective tissue disorders & vasculitis, not complicated 
242A Infectious arthritis and bursitis 
242B Inflammatory arthropathies, complicated 
242C Inflammatory arthropathies, not complicated 
242D Other arthritis 
242E Arthroses, complicated 
242F Arthroses, not complicated 
243 Medical back problems 
244 Other bone diseases, complicated 
245 Other bone diseases, not complicated 
247 Symptoms of musculoskeletal system & connective tissue disorders 
248 Bursitis, tendonitis & myositis 
249 Aftercare, musculoskeletal system & connective tissue 
250 Fracture/sprain/dislocation in forearm/hand/foot, >17 year, complicated 
251 Fracture/sprain/dislocation in forearm/hand/foot, >17 year, not complicated 
252 Fracture/sprain/dislocation in forearm/hand/foot, 0-17 year 
253 Fracture/sprain/dislocation in upper arm/lower leg except foot, >17 year, 
complicated 
254 Fracture/sprain/dislocation in upper arm/lower leg except foot, >17 year, not 
complicated 
255 Fracture/sprain/dislocation in upper arm/lower leg except foot, 0-17 year 
256 Other musculoskeletal system & connective tissue diagnoses 
 
 
 
B Resource use in health care 
Table 3: Number (percent) of hospital-bed days, admissions and patients receiving inpatient care in hospitals in 2012 (Socialstyrelsen, 2012d).  
 
ICD-10-SE  Hospital-bed days Hospital admissions Patients 
M00-M99 Diseases of the musculoskeletal system and connective tissue  449 699 96 020 78 498 
    
M00-M03 Infectious arthropathies 19259 (4 %) 2229 (2 %) 1848 (2 %) 
M05-M14 Inflammatory polyarthropathies 30013 (7 %) 5160 (5 %) 4335 (6 %) 
M15-M19 Arthrosis 135769 (30 %) 32354 (34 %) 29006 (37 %) 
M20-M25 Other joint disorders 15397 (3 %) 6442 (7 %) 5473 (7 %) 
M30-M36 Systemic connective tissue disorders 26552 (6 %) 4029 (4 %) 2646 (3 %) 
M40-M43 Deforming dorsopathies 8516 (2 %) 1334 (1 %) 1131 (1 %) 
M45-M49 Spondylopathies 74394 (17 %) 11942 (12 %) 9209 (12 %) 
M50-M54 Other dorsopathies 57798 (13 %) 13859 (14 %) 11402 (15 %) 
M60-M63 Disorders of muscles 2873 (1 %) 517 (1 %) 471 (1 %) 
M65-M68 Disorders of synovium and tendon 2936 (1 %) 1055 (1 %) 971 (1 %) 
M70-M79 Other soft tissue disorders 30819 (7 %) 9614 (10 %) 8901 (11 %) 
M80-M85 Disorders of bone density and structure 17370 (4 %) 2782 (3 %) 2473 (3 %) 
M86-M90 Other osteopathies 16383 (4 %) 2167 (2 %) 1756 (2 %) 
M91-M94 Chondropathies 1309 (0,3 %) 568 (1 %) 532 (1 %) 
M95-M99 Other disorders of the musculoskeletal system  
and connective tissue 
10311 (2 %) 1968 (2 %) 1381 (2 %) 
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Table 4: Total health care costs in 2012 for musculoskeletal disorders defined by DRG groups in MDC 08 (Socialstyrelsen, 2012b; SKL, 2012). 
   
Total health care cost, SEK 
thousands 
MDC 
Hospital 
admissions 
Average cost per 
hospital-bed day, 
SEK 
Based on 
admissions 
Based on 
hospital-bed 
days 
MDC 08 (all) 169724 708654 9705997 8865759 
209 Join replacement of hip, knee and foot 35536 67908 2824706 2527115 
210-212 Hip and femur procedures  15093 35349 1092326 1024663 
214-215 Back and neck procedures 13255 88461 1185652 1003917 
217 Wound debridement and skin graft 463 12124 74973 85568 
218-220 Foot, lower leg or upper arm procedures 11427 45681 728335 669855 
221-222 Knee procedures 3422 25917 194968 149914 
223-224 Arm procedures 9294 52633 508240 439694 
225 Foot procedures 1136 15052 51161 44629 
226-227 Connective tissue procedures 3466 27124 171375 157830 
228-229 Hand and wrist procedures 5770 38460 224682 210728 
230-231 Excision and removal int fix device 1466 26755 54164 53363 
233-234 Other musculoskeletal system and connective tissue procedures 2002 34751 157751 139064 
235-237 Fractures of hip, pelvis and thigh 5782 21152 264063 205722 
239 Musculoskeletal malignancy 3022 7743 161381 151609 
240-241 Connective tissue disorders and vasculitis 4024 16245 213607 207120 
242 Arthritis and arthroses 6803 40224 279373 272338 
243 Medical back problems 14434 7236 464039 436103 
244-245 Other bone diseases 2394 11861 101140 91375 
247 Symptoms of musculoskeletal system and connective tissue disorders 5682 7488 127947 122116 
2448 Bursitis, tendonitis and myositis 1674 9573 75397 67679 
249 Aftercare, musculoskeletal system and connective tissue 2907 6507 124341 112207 
250-255 Fracture, sprain or dislocation in arm, hand or foot 17803 63588 468118 547517 
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C Productivity costs 
Table 5: Productivity costs due to reduced ability to work (Försäkringskassan, 2012).  
Type of productivity cost Units Value7, 
  SEK million 
Sickness benefit (number of cases)     
Male total 196 178  
Caused by MSDs (28 %) 54 340  
Female total  331 157  
Caused by MSDs (24 %) 78 403  
Sickness benefit (total number of days)   
Male (net) 4 173 727  
Female (net) 6 618 652  
Summed number of days with sickness benefit8   
Male 4 934 487 11 469 
Female 7 716 294 15 421 
Total male and female 12 650 781 26 890 
Sickness and activity compensation (number of persons)     
Male total 157 029  
Caused by MSDs (19 %) 29 887  
With full scope (61.9 %) 18 507 10 109 
Weighting other compensation levels (n=11380)9  3 001 
Summed productivity cost male  13 110 
Female total 220 836  
Caused by MSDs (32 %) 70 698  
With full scope (60.2 %) 39 926 18 751 
Weighting other compensation levels (n=30772)   6 560 
Summed productivity cost female  25 311 
Total men and female (unweigthed) 100 585  
Total male and female  
(weighted corresponding to full year compensation)  77 895 38 421 
Total productivity cost due to reduced ability to work   65 311 
 
 
 
                                                 
7 The HC approach has been used to evaluate productivity cost as the average monthly salary for men 
(SEK 32,100) and women (SEK 27,600) for the year 2012 including social security contributions (31.42 
%) and collective wage agreement (10.38 %). One year comprises working hours equivalent to 47 work 
weeks comprising 5 business days, which gives a total of 235 working days. 
8 Includes registered cases with sickness benefit that exceeded 14 days and the first 14 days which the 
employer pays sick pay. Absences that are less than 15 days are not included in the calculation.   
9 Weighting made for productivity costs for different benefit levels (1/1, 1/2, 1/4 and 2/3). 
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Table 6: Productivity costs due to premature death in MSD M00-M99 in 2012. Males 
(Socialstyrelsen, 2012c; SCB, 2012b). 
Age 
M00-
M99 
Lost years 
(median 
values in the 
interval) 
Number of 
lost working 
years (in 
ages 20-65 ) 
Estimated 
life 
expectancy 
of median 
value 
Expected activity 
given 
unemployment 
and hours worked 
in the age group 
according to AKU Employed  
    Year % % 
0-4 0 78.11 0 80.11 0  
5-9 1 73.15 45 80.15 0  
10-14 0 68.19 0 80.19 0  
15-19 1 63.23 45 80.23 37.9 16 
20-24 0 58.36 0 80.36 69.6 58.5 
25-29 0 53.56 0 80.56 89.8 84 
30-34 0 48.73 0 80.73 89.8 84 
35-39 0 43.88 0 80.88 97.3 91 
40-44 2 39.07 46 81.07 97.3 91 
45-49 2 34.30 36 81.30 98.2 88.2 
50-54 5 29.66 65 81.66 98.2 88.2 
55-59 4 25.20 32 82.20 93.6 76.4 
60-64 8 20.89 24 82.89 93.6 76.4 
65-69 11 16.84  83.84 66.3 18.9 
70-74 13 13.04  85.04 66.3 18.9 
75-79 25 9.68  86.68 0  
80-84 20 6.83  88.83 0  
85+ 53 4.61  91.61 0  
Total 145  293    
 
 
 
 
 
 
 
  
        38 
 
Table 7: Productivity costs and the discounted value of lost production due to premature death in MSD M00-M99 in 2012. Males.   
  The value of lost production for each age interval (discounted 3 %)   
 ICD M00-M99         
Age Number of deaths   15-19 20-24 25-34 35-44 45-54 55-64 65-74 Sum 
 Year 2012         
0-4 0 0 0 0 0 0 0 0 0 
5-9 1 79 026 457 707 1 532 175 1 338 242 974 066 598 419 78 026 5 057 660 
10-14 0 0 0 0 0 0 0 0 0 
15-19 1 38 345 457 707 1 532 175 1 338 242 974 066 598 419 78 026 5 016 979 
20-24 0  0 0 0 0 0 0 0 
25-29 0   0 0 0 0 0 0 
30-34 0   0 0 0 0 0 0 
35-39 0    0 0 0 0 0 
40-44 2    534 817 1 948 131 1 196 837 156 052 3 835 838 
45-49 2     1 469 370 1 196 837 156 052 2 822 259 
50-54 5     973 193 2 992 093 390 130 4 355 416 
55-59 4      1 805 419 312 104 2 117 523 
60-64 8      956 612 624 208 1 580 819 
65-69 11       647 358 647 358 
70-74 13       202 686 202 686 
75-79 25         
80-84 20         
85+ 53         
Total 145        25 636 537 
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Table 8: Productivity costs due to premature death in MSD M00-M99 in 2012. Females 
(Socialstyrelsen, 2012c; SCB, 2012b). 
Age 
M00-
M99 
Lost years 
(median 
values in the 
interval) 
Number of 
lost working 
years (in 
ages 20-65 ) 
Estimated 
life 
expectancy 
of median 
value 
Expected activity 
given 
unemployment 
and hours worked 
in the age group 
according to AKU Employed  
    Year % % 
0-4 1 81.74 45 83.74 0  
5-9 0 76.77 0 83.77 0  
10-14 2 71.80 90 83.80 0  
15-19 1 66.85 45 83.85 30.1 23.2 
20-24 0 61.91 0 83.91 61.8 57.4 
25-29 0 56.97 0 83.97 82.8 77.3 
30-34 1 52.04 33 84.04 82.8 77.3 
35-39 1 47.14 28 84.14 87.1 85.2 
40-44 1 42.27 23 84.27 87.1 85.2 
45-49 4 37.46 72 84.46 88.9 84.7 
50-54 5 32.73 65 84.73 88.9 84.7 
55-59 5 28.12 40 85.12 84.9 69.8 
60-64 12 23.63 36 85.63 84.9 69.8 
65-69 18 19.35  86.35 51.8 10.9 
70-74 27 15.29  87.29 51.8 10.9 
75-79 43 11.54  88.54 0  
80-84 46 8.22  90.22 0  
85+ 143 5.53  92.53 0  
Total 310  477    
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Table 9: Productivity costs and the discounted value of lost production due to premature death in MSD M00-M99 in 2012. Females.  
  The value of lost production for each age interval (discounted 3 %)   
 ICD M00-M99         
Age Number of deaths   15-19 20-24 25-34 35-44 45-54 55-64 65-74 Sum 
 Year 2012         
0-4 1 78 247 342 868 1 117 806 964 367 728 111 426 386 30 229 3 688 014 
5-9 0 0 0 0 0 0 0 0 0 
10-14 2 156 494 685 736 2 235 613 1 928 734 1 456 222 852 772 60 458 7 376 028 
15-19 1 37 967 342 868 1 117 806 964 367 728 111 426 386 30 229 3 647 735 
20-24 0  0 0 0 0 0 0 0 
25-29 0   0 0 0 0 0 0 
30-34 1   223 361 964 367 728 111 426 386 30 229 2 372 454 
35-39 1    727 370 728 111 426 386 30 229 1 912 096 
40-44 1    192 700 728 111 426 386 30 229 1 377 427 
45-49 4     2 196 698 1 705 545 120 916 4 023 159 
50-54 5     727 458 2 131 931 151 145 3 010 534 
55-59 5      1 608 000 151 145 1 759 145 
60-64 12      1 022 410 362 748 1 385 158 
65-69 18       410 402 410 402 
70-74 27       163 090 163 090 
75-79 43         
80-84 46         
85+ 143         
Total 310       31 125 241 
 
